{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:37:39Z","timestamp":1790127459120,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"29","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T00:00:00Z","timestamp":1574467200000},"content-version":"vor","delay-in-days":22,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004581","name":"Ministerium f\u00fcr Wissenschaft, Forschung und Kultur","doi-asserted-by":"publisher","award":["06-GeCa:H228-05\/002\/004"],"award-info":[{"award-number":["06-GeCa:H228-05\/002\/004"]}],"id":[{"id":"10.13039\/501100004581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Anal Bioanal Chem"],"published-print":{"date-parts":[[2019,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The rapid and simultaneous detection of DNA and protein biomarkers is necessary to detect the outbreak of a disease or to monitor a disease. For example, cardiovascular diseases are a major cause of adult mortality worldwide. We have developed a rapidly adaptable platform to assess biomarkers using a microfluidic technology. Our model mimics autoantibodies against three proteins, C-reactive protein (CRP), brain natriuretic peptide (BNP), and low-density lipoprotein (LDL). Cell-free mitochondrial DNA (cfmDNA) and DNA controls are detected via fluorescence probes. The biomarkers are covalently bound on the surface of size- (11\u201315 \u03bcm) and dual-color encoded microbeads and immobilized as planar layer in a microfluidic chip flow cell. Binding events of target molecules were analyzed by fluorescence measurements with a fully automatized fluorescence microscope (end-point and real-time) developed in house. The model system was optimized for buffers and immobilization strategies of the microbeads to enable the simultaneous detection of protein and DNA biomarkers. All prime target molecules (anti-CRP, anti-BNP, anti-LDL, cfmDNA) and the controls were successfully detected both in independent reactions and simultaneously. In addition, the biomarkers could also be detected in spiked human serum in a similar way as in the optimized buffer system. The detection limit specified by the manufacturer is reduced by at least a factor of five for each biomarker as a result of the antibody detection and kinetic experiments indicate that nearly 50 % of the fluorescence intensity is achieved within 7 min. For rapid data inspection, we have developed the open source software <jats:italic>digilogger<\/jats:italic>, which can be applied for data evaluation and visualization.<\/jats:p>","DOI":"10.1007\/s00216-019-02199-x","type":"journal-article","created":{"date-parts":[[2019,11,23]],"date-time":"2019-11-23T07:02:41Z","timestamp":1574492561000},"page":"7725-7735","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Simultaneous detection and quantification of DNA and protein biomarkers in spectrum of cardiovascular diseases in a microfluidic microbead chip"],"prefix":"10.1007","volume":"411","author":[{"given":"Franziska","family":"Dinter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Burdukiewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schierack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Werner","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Nestler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Dame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1441-6512","authenticated-orcid":false,"given":"Stefan","family":"R\u00f6diger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,23]]},"reference":[{"key":"2199_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/971453","volume":"2015","author":"RK Upadhyay","year":"2015","unstructured":"Upadhyay RK. Emerging risk biomarkers in cardiovascular diseases and disorders. J Lipids. 2015;2015:1\u201350.","journal-title":"J Lipids"},{"key":"2199_CR2","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","volume":"69","author":"National Institutes of HealthDirector\u2019s Initiative on Biomarkers and Surrogate Endpoints","year":"2001","unstructured":"National Institutes of HealthDirector\u2019s Initiative on Biomarkers and Surrogate Endpoints. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001;69:89\u201395.","journal-title":"Clin Pharmacol Ther"},{"key":"2199_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.clinbiochem.2009.01.019","volume":"42","author":"B McDonnell","year":"2009","unstructured":"McDonnell B, Hearty S, Leonard P, O\u2019Kennedy R. Cardiac biomarkers and the case for point-of-care testing. Clin Biochem. 2009;42:549\u201361.","journal-title":"Clin Biochem"},{"key":"2199_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.tcm.2016.07.005","volume":"27","author":"R Dhingra","year":"2017","unstructured":"Dhingra R, Vasan RS. Biomarkers in cardiovascular disease: statistical assessment and section on key novel heart failure biomarkers. Trends Cardiovasc Med. 2017;27:123\u201333.","journal-title":"Trends Cardiovasc Med"},{"key":"2199_CR5","doi-asserted-by":"publisher","unstructured":"Berezin EA. Circulating cell-free mitochondrial DNA as biomarker of cardiovascular risk: new challenges of old findings. Angiol. 2015. https:\/\/doi.org\/10.4172\/2329-9495.1000161.","DOI":"10.4172\/2329-9495.1000161"},{"key":"2199_CR6","doi-asserted-by":"publisher","unstructured":"Albert MA. Biomarkers and heart disease. J Clin Sleep Med. 2011. https:\/\/doi.org\/10.5664\/jcsm.1342.","DOI":"10.5664\/jcsm.1342"},{"key":"2199_CR7","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1007\/s00216-019-01601-y","volume":"411","author":"S Peng","year":"2019","unstructured":"Peng S, Hong T, Liang W, Liu W, Chen C. A multichannel microchip containing 16 chambers packed with antibody-functionalized beads for immunofluorescence assay. Anal Bioanal Chem. 2019;411:1579\u201389.","journal-title":"Anal Bioanal Chem"},{"key":"2199_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1042\/BCJ20170714","volume":"475","author":"H Nakayama","year":"2018","unstructured":"Nakayama H, Otsu K. Mitochondrial DNA as an inflammatory mediator in cardiovascular diseases. Biochem J. 2018;475:839\u201352.","journal-title":"Biochem J"},{"key":"2199_CR9","doi-asserted-by":"publisher","unstructured":"Berezin AE (2016) DTOhI: 1e0.21C76e7\/l2l1-72F-0r4e79e.100M068itochondrial DNA: a novel biomarker of cardiovascular risk? Transl Biomed 4. https:\/\/doi.org\/10.21767\/2172-0479.100068.","DOI":"10.21767\/2172-0479.100068"},{"key":"2199_CR10","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1128\/AEM.56.6.1919-1925.1990","volume":"56","author":"RI Amann","year":"1990","unstructured":"Amann RI, Devereux R, Stahl\u2019 DA. Combination of 16S rRNA-targeted oligonucleotide probes with flow cytometry for analyzing mixed microbial populations. Appl Environ Microbiol. 1990;56:7.","journal-title":"Appl Environ Microbiol"},{"key":"2199_CR11","doi-asserted-by":"publisher","unstructured":"Meier LA, Binstadt BA. The contribution of autoantibodies to inflammatory cardiovascular pathology. Front Immunol. 2018. https:\/\/doi.org\/10.3389\/fimmu.2018.00911.","DOI":"10.3389\/fimmu.2018.00911"},{"issue":"11","key":"2199_CR12","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.3899\/jrheum.090188","volume":"36","author":"KIMBERLY P. LIANG","year":"2009","unstructured":"Liang KP, Maradit-Kremers H, Crowson CS, Snyder MR, Therneau TM, Roger VL, et al. Autoantibodies and the risk of cardiovascular events. J Rheumatol. 2009;36:2462\u20139. https:\/\/doi.org\/10.3899\/jrheum.090188.","journal-title":"The Journal of Rheumatology"},{"key":"2199_CR13","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/B978-0-12-803267-1.00027-2","volume-title":"The Heart in Rheumatic, Autoimmune and Inflammatory Diseases","author":"J. M\u00fcller","year":"2017","unstructured":"M\u00fcller J, Wallukat G, Schimke I (2017) Autoantibody-directed therapy in cardiovascular diseases. In: Heart Rheum. Autoimmune Inflamm. Dis. Elsevier, pp 659\u2013679. https:\/\/doi.org\/10.1016\/B978-0-12-803267-1.00027-2."},{"key":"2199_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S1568-9972(02)00059-9","volume":"1","author":"J Frosteg\u00e5rd","year":"2002","unstructured":"Frosteg\u00e5rd J. Autoimmunity, oxidized LDL and cardiovascular disease. Autoimmun Rev. 2002;1:233\u20137.","journal-title":"Autoimmun Rev"},{"key":"2199_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1136\/ard.2007.073312","volume":"66","author":"SG O\u2019Neill","year":"2007","unstructured":"O\u2019Neill SG, Isenberg DA, Rahman A. Could antibodies to C-reactive protein link inflammation and cardiovascular disease in patients with systemic lupus erythematosus? Ann Rheum Dis. 2007;66:989\u201391.","journal-title":"Ann Rheum Dis"},{"key":"2199_CR16","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.cca.2008.10.002","volume":"400","author":"J Wetter\u00f6","year":"2009","unstructured":"Wetter\u00f6 J, Nilsson L, Jonasson L, Sj\u00f6wall C. Reduced serum levels of autoantibodies against monomeric C-reactive protein (CRP) in patients with acute coronary syndrome. Clin Chim Acta. 2009;400:128\u201331.","journal-title":"Clin Chim Acta"},{"key":"2199_CR17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1002\/art.27286","volume":"62","author":"SG O\u2019Neill","year":"2010","unstructured":"O\u2019Neill SG, Giles I, Lambrianides A, Manson J, D\u2019Cruz D, Schrieber L, et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum. 2010;62:845\u201354.","journal-title":"Arthritis Rheum"},{"key":"2199_CR18","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.atherosclerosis.2005.12.013","volume":"189","author":"PWF Wilson","year":"2006","unstructured":"Wilson PWF, Ben-Yehuda O, McNamara J, Massaro J, Witztum J, Reaven PD. Autoantibodies to oxidized LDL and cardiovascular risk: the Framingham Offspring Study. Atherosclerosis. 2006;189:364\u20138.","journal-title":"Atherosclerosis"},{"key":"2199_CR19","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1046\/j.1365-2796.2000.00657.x","volume":"247","author":"O Vaarala","year":"2000","unstructured":"Vaarala O. Autoantibodies to modified LDLs and other phospholipid-protein complexes as markers of cardiovascular diseases. J Intern Med. 2000;247:381\u20134.","journal-title":"J Intern Med"},{"key":"2199_CR20","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1093\/cvr\/cvx112","volume":"113","author":"RA Iseme","year":"2017","unstructured":"Iseme RA, McEvoy M, Kelly B, Agnew L, Walker FR, Handley T, et al. A role for autoantibodies in atherogenesis. Cardiovasc Res. 2017;113:1102\u201312.","journal-title":"Cardiovasc Res"},{"key":"2199_CR21","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1007\/s00604-014-1243-4","volume":"181","author":"S R\u00f6diger","year":"2014","unstructured":"R\u00f6diger S, Liebsch C, Schmidt C, Lehmann W, Resch-Genger U, Schedler U, et al. Nucleic acid detection based on the use of microbeads: a review. Microchim Acta. 2014;181:1151\u201368.","journal-title":"Microchim Acta"},{"key":"2199_CR22","doi-asserted-by":"publisher","first-page":"064001","DOI":"10.1088\/1361-6439\/aab0ca","volume":"28","author":"P Streit","year":"2018","unstructured":"Streit P, Nestler J, Shaporin A, Graunitz J, Otto T. Design methodology and results evaluation of a heating functionality in modular lab-on-chip systems. J Micromech Microeng. 2018;28:064001.","journal-title":"J Micromech Microeng"},{"key":"2199_CR23","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1039\/C1LC20693A","volume":"12","author":"S Schumacher","year":"2012","unstructured":"Schumacher S, Nestler J, Otto T, et al. Highly-integrated lab-on-chip system for point-of-care multiparameter analysis. Lab Chip. 2012;12:464\u201373.","journal-title":"Lab Chip"},{"key":"2199_CR24","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/mi7090153","volume":"7","author":"S Geidel","year":"2016","unstructured":"Geidel S, Peransi Llopis S, Rodrigo M, de Diego-Castilla G, Sousa A, Nestler J, et al. Integration of an optical ring resonator biosensor into a self-contained microfluidic cartridge with active, single-shot micropumps. Micromachines. 2016;7:153.","journal-title":"Micromachines"},{"key":"2199_CR25","doi-asserted-by":"publisher","first-page":"3379","DOI":"10.1021\/ac103277s","volume":"83","author":"S R\u00f6diger","year":"2011","unstructured":"R\u00f6diger S, Ruhland M, Schmidt C, Schr\u00f6der C, Grossmann K, B\u00f6hm A, et al. Fluorescence dye adsorption assay to quantify carboxyl groups on the surface of poly(methyl methacrylate) microbeads. Anal Chem. 2011;83:3379\u201385.","journal-title":"Anal Chem"},{"key":"2199_CR26","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/10_2011_132","volume-title":"Mol. Diagn","author":"S R\u00f6diger","year":"2012","unstructured":"R\u00f6diger S, Schierack P, B\u00f6hm A, et al. A highly versatile microscope imaging technology platform for the multiplex real-time detection of biomolecules and autoimmune antibodies. In: Seitz H, Schumacher S, editors. Mol. Diagn. Heidelberg: Springer; 2012. p. 35\u201374."},{"key":"2199_CR27","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1006\/prep.1998.0930","volume":"14","author":"A Gallizia","year":"1998","unstructured":"Gallizia A, de Lalla C, Nardone E, Santambrogio P, Brandazza A, Sidoli A, et al. Production of a soluble and functional recombinant streptavidin in Escherichia coli. Protein Expr Purif. 1998;14:192\u20136.","journal-title":"Protein Expr Purif"},{"key":"2199_CR28","unstructured":"R Core Team (2018) R: a language and environment for statistical computing. R Found Stat Comput https:\/\/www.R-project.org\/."},{"key":"2199_CR29","doi-asserted-by":"publisher","first-page":"e0146021","DOI":"10.1371\/journal.pone.0146021","volume":"10","author":"C Ritz","year":"2015","unstructured":"Ritz C, Baty F, Streibig JC, Gerhard D. Dose-response analysis using R. PLoS One. 2015;10:e0146021.","journal-title":"PLoS One"},{"key":"2199_CR30","doi-asserted-by":"publisher","unstructured":"Prosperi M, Min JS, Bian J, Modave F. Big data hurdles in precision medicine and precision public health. BMC Med Inform Decis Mak. 2018. https:\/\/doi.org\/10.1186\/s12911-018-0719-2.","DOI":"10.1186\/s12911-018-0719-2"},{"key":"2199_CR31","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1038\/aps.2018.29","volume":"39","author":"M Adamcova","year":"2018","unstructured":"Adamcova M, \u0160imko F. Multiplex biomarker approach to cardiovascular diseases. Acta Pharmacol Sin. 2018;39:1068\u201372.","journal-title":"Acta Pharmacol Sin"},{"key":"2199_CR32","doi-asserted-by":"publisher","first-page":"2934","DOI":"10.3390\/s17122934","volume":"17","author":"J Wu","year":"2017","unstructured":"Wu J, Dong M, Santos S, Rigatto C, Liu Y, Lin F. Lab-on-a-chip platforms for detection of cardiovascular disease and cancer biomarkers. Sensors. 2017;17:2934.","journal-title":"Sensors"},{"key":"2199_CR33","doi-asserted-by":"publisher","DOI":"10.5772\/intechopen.75200","volume-title":"Autoantibodies and Cytokines","author":"Farhanah Aziz","year":"2019","unstructured":"Aziz F, Smith M, Blackburn JM. Autoantibody-based diagnostic biomarkers: technological approaches to discovery and validation. Autoantibodies Cytokines. 2019. https:\/\/doi.org\/10.5772\/intechopen.75200."},{"key":"2199_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/sms.12702","volume":"27","author":"JJ Bass","year":"2017","unstructured":"Bass JJ, Wilkinson DJ, Rankin D, Phillips BE, Szewczyk NJ, Smith K, et al. An overview of technical considerations for Western blotting applications to physiological research. Scand J Med Sci Sports. 2017;27:4\u201325.","journal-title":"Scand J Med Sci Sports"},{"key":"2199_CR35","doi-asserted-by":"publisher","first-page":"e77089","DOI":"10.1371\/journal.pone.0077089","volume":"8","author":"M Welvaert","year":"2013","unstructured":"Welvaert M, Rosseel Y. On the definition of signal-to-noise ratio and contrast-to-noise ratio for fMRI data. PLoS One. 2013;8:e77089.","journal-title":"PLoS One"},{"key":"2199_CR36","doi-asserted-by":"publisher","first-page":"9462","DOI":"10.1021\/acsami.7b00418","volume":"9","author":"X Liu","year":"2017","unstructured":"Liu X, Bing T, Shangguan D. Microbead-based platform for multiplex detection of DNA and protein. ACS Appl Mater Interfaces. 2017;9:9462\u20139.","journal-title":"ACS Appl Mater Interfaces"},{"key":"2199_CR37","doi-asserted-by":"publisher","unstructured":"Schneider J, Weiss R, Ruhe M, Jung T, Roggenbuck D, Stohwasser R, Schierack P, R\u00f6diger S Open source bioimage informatics tools for the analysis of DNA damage and associated biomarkers. J Lab Precis Med. 2019;4:0. https:\/\/doi.org\/10.21037\/jlpm.2019.04.05.","DOI":"10.21037\/jlpm.2019.04.05"},{"key":"2199_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.bios.2019.01.068","volume":"132","author":"J Liu","year":"2019","unstructured":"Liu J, Geng Z, Fan Z, Liu J, Chen H. Point-of-care testing based on smartphone: the current state-of-the-art (2017-2018). Biosens Bioelectron. 2019;132:17\u201337.","journal-title":"Biosens Bioelectron"},{"key":"2199_CR39","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1007\/s00216-011-5174-1","volume":"401","author":"MS Wang","year":"2011","unstructured":"Wang MS, Black JC, Knowles MK, Reed SM. C-reactive protein (CRP) aptamer binds to monomeric but not pentameric form of CRP. Anal Bioanal Chem. 2011;401:1309\u201318.","journal-title":"Anal Bioanal Chem"}],"container-title":["Analytical and Bioanalytical Chemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-019-02199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00216-019-02199-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00216-019-02199-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,22]],"date-time":"2020-11-22T00:46:20Z","timestamp":1606005980000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00216-019-02199-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":39,"journal-issue":{"issue":"29","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["2199"],"URL":"https:\/\/doi.org\/10.1007\/s00216-019-02199-x","relation":{},"ISSN":["1618-2642","1618-2650"],"issn-type":[{"value":"1618-2642","type":"print"},{"value":"1618-2650","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"11 June 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Werner Lehmann has a management role in and is a shareholder of attomol GmbH. This company is a diagnostic manufacturer. Joerg Nestler is managing director and shareholder of BiFlow Systems GmbH. All other authors declare that they have no competing financial and nonfinancial interests.The studies on blood material (serum) have been granted by the ethics committee of the Brandenburg University of Technology (BTU) Cottbus-Senftenberg, Cottbus, Germany, (Ethikkommissionssatzung BTU, document number EK2018\u20143) and were conducted in accordance with the Helsinki Declaration of 1964 (revised 2008). The blood donor gave a written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}